Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • AChE
    (1)
  • Endogenous Metabolite
    (1)
  • HBV
    (1)
  • Histamine Receptor
    (1)
  • Proton pump
    (1)
  • Sodium Channel
    (1)
Filter
Search Result
Results for "

esophagitis

" in TargetMol Product Catalog
  • Inhibitor Products
    8
    TargetMol | Activity
  • Recombinant Protein
    3
    TargetMol | inventory
  • Inhibitory Antibodies
    2
    TargetMol | natural
  • Isotope products
    2
    TargetMol | composition
  • Natural Products
    1
    TargetMol | Activity
Oxethazaine
T0044126-27-2
Oxethazaine (Oxetacaine), a topical anesthetic, is used to prevent acid-induced esophageal pain.
  • $41
In Stock
Size
QTY
TargetMol | Citations Cited
Dectrekumab
T805991528523-94-5
Dectrekumab (QAX576), a humanized monoclonal antibody targeting IL-13, significantly reduces intraepithelial esophageal eosinophil counts and normalizes dysregulated esophageal disease-related transcripts in Eosinophilic esophagitis (EoE), offering sustained benefits. It is valuable for inflammation and immunology research [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Cendakimab
T769422151032-62-9
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective humanized recombinant monoclonal antibody targeting the IL-13 molecule with high specificity. It demonstrates potent affinity for both the wild-type and variant forms of human IL-13, effectively inhibiting IL-13's interaction with its receptors, IL-13Rα1 and IL-13Rα2, as evidenced by IC50 values of 352 pM and 631 pM, respectively, determined via ELISA. Furthermore, Cendakimab binds with comparable affinities of 52 pM and 50 pM to the wild-type human IL-13 and its common R110Q polymorphic variant. This antibody holds therapeutic potential for treating IL-13-related allergic and inflammatory conditions, such as asthma and eosinophilic esophagitis.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Nizatidine
T157576963-41-2
Nizatidine (Acinon) is a competitive and reversible histamine H2-receptor antagonist with antacid activity.
  • $41
In Stock
Size
QTY
Vonoprazan-d4
TMIH-0602
Vonoprazan-d4 is a deuterated compound of Vonoprazan. Vonoprazan has a CAS number of 881681-00-1. Vonoprazan is an orally active potassium-competitive acid blocker.Vonoprazan can be used for the treatment of gastroduodenal ulcer and reflux esophagitis
  • $457
7-10 days
Size
QTY
Vonoprazan-d3
TMIH-0601
Vonoprazan-d3 is a deuterated compound of Vonoprazan. Vonoprazan has a CAS number of 881681-00-1. Vonoprazan is an orally active potassium-competitive acid blocker.Vonoprazan can be used for the treatment of gastroduodenal ulcer and reflux esophagitis
  • $457
7-10 days
Size
QTY
Vonoprazan
T8388881681-00-1
Vonoprazan (TAK-438 (free base)) is an orally active potassium-competitive acid blocker.Vonoprazan can be used for the treatment of gastroduodenal ulcer and reflux esophagitis
  • $29
In Stock
Size
QTY
3-Methyl-L-histidine
T8274368-16-1
3-Methylhistidine belongs to the class of organic compounds known as histidine and derivatives. Histidine and derivatives are compounds containing cysteine or a derivative thereof resulting from reaction of cysteine at the amino group or the carboxy group
  • $37
In Stock
Size
QTY